1. Home
  2. LEGN vs VCTR Comparison

LEGN vs VCTR Comparison

Compare LEGN & VCTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • VCTR
  • Stock Information
  • Founded
  • LEGN 2014
  • VCTR 2013
  • Country
  • LEGN United States
  • VCTR United States
  • Employees
  • LEGN N/A
  • VCTR 460
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • VCTR Investment Managers
  • Sector
  • LEGN Health Care
  • VCTR Finance
  • Exchange
  • LEGN Nasdaq
  • VCTR Nasdaq
  • Market Cap
  • LEGN 5.4B
  • VCTR 4.3B
  • IPO Year
  • LEGN 2020
  • VCTR 2018
  • Fundamental
  • Price
  • LEGN $38.96
  • VCTR $64.70
  • Analyst Decision
  • LEGN Strong Buy
  • VCTR Buy
  • Analyst Count
  • LEGN 12
  • VCTR 10
  • Target Price
  • LEGN $73.91
  • VCTR $70.80
  • AVG Volume (30 Days)
  • LEGN 1.6M
  • VCTR 356.4K
  • Earning Date
  • LEGN 08-08-2025
  • VCTR 08-07-2025
  • Dividend Yield
  • LEGN N/A
  • VCTR 3.03%
  • EPS Growth
  • LEGN N/A
  • VCTR 38.50
  • EPS
  • LEGN N/A
  • VCTR 4.50
  • Revenue
  • LEGN $728,303,000.00
  • VCTR $897,222,000.00
  • Revenue This Year
  • LEGN $65.49
  • VCTR $46.06
  • Revenue Next Year
  • LEGN $53.76
  • VCTR $16.25
  • P/E Ratio
  • LEGN N/A
  • VCTR $14.37
  • Revenue Growth
  • LEGN 112.46
  • VCTR 7.38
  • 52 Week Low
  • LEGN $27.34
  • VCTR $43.82
  • 52 Week High
  • LEGN $60.87
  • VCTR $73.42
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 66.26
  • VCTR 55.74
  • Support Level
  • LEGN $34.64
  • VCTR $64.06
  • Resistance Level
  • LEGN $39.88
  • VCTR $66.37
  • Average True Range (ATR)
  • LEGN 1.46
  • VCTR 1.57
  • MACD
  • LEGN 0.37
  • VCTR 0.11
  • Stochastic Oscillator
  • LEGN 87.67
  • VCTR 73.76

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About VCTR Victory Capital Holdings Inc.

Victory Capital Holdings Inc is an independent investment management firm. The company operates its business through franchises and solutions platform. It provides centralized distribution, marketing, and operations infrastructure to the company's franchises and solutions platform. The company operates through one business segment that is Investment management services and products to institutional, intermediary, retirement platforms, and individual investors. The franchises and solutions platform manages a variety of investment strategies for its customers. It derives majority of its revenues from asset-based fees from investment management products and services to individuals and institutions.

Share on Social Networks: